ES2031821T3 - Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo. - Google Patents

Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.

Info

Publication number
ES2031821T3
ES2031821T3 ES198686307911T ES86307911T ES2031821T3 ES 2031821 T3 ES2031821 T3 ES 2031821T3 ES 198686307911 T ES198686307911 T ES 198686307911T ES 86307911 T ES86307911 T ES 86307911T ES 2031821 T3 ES2031821 T3 ES 2031821T3
Authority
ES
Spain
Prior art keywords
sulfur
hydrogen
group
methylene
oxygen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198686307911T
Other languages
English (en)
Inventor
William John Coates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smith Kline and French Laboratories Ltd
Original Assignee
Smith Kline and French Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858525654A external-priority patent/GB8525654D0/en
Priority claimed from GB868601667A external-priority patent/GB8601667D0/en
Application filed by Smith Kline and French Laboratories Ltd filed Critical Smith Kline and French Laboratories Ltd
Application granted granted Critical
Publication of ES2031821T3 publication Critical patent/ES2031821T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE DESCRIBEN COMPUESTOS DE LA FORMULA (I), Y SUS SALES ACEPTABLES FARMACEUTICAMENTE EN LAS QUE A ES UN GRUPO DE SUB-FORMULAS (A), (B), (C) O (D) X ES CHR1, AZUFRE, OXIGENO O NH, R1 ES HIDROGENO O R1 Y R2 FORMAN UN ENLACE, R2 ES HIDROGENO O METILO, O R1 Y R2 FORMAN UN ENLACE, R3 ES HIDROGENO O CON R4 FORMA UN METILENO O UN GRUPO 1,2-ETANODIILO, 4 ES AZUFRE, OXIGENO O NH, Z ES AZUFRE U OXIGENO, R4 ES HIDROGENO O CON R3 FORMA UN METILENO O UN GRUPO 1,2-ETANODIILO, CON LA CONDICION DE QUE X ES CHR1 O AZUFRE CUANDO R3 JUNTO CON R4 FORMAN UN METILENO O UN GRUPO 1,2-ETANDIILO. ESTOS COMPUESTOS TIENEN PROPIEDADES INOTROPICAS, VASODILATADORAS, BRONCODILATADORAS, E INHIBIDORAS DE LA AGRAGACION DE PLAQUETAS. SE DESCRIBEN LAS PREPARACIONES FARMACEUTICAS QUE LAS CONTIENEN Y LOS METODOS DE SU USO. SE DESCRIBEN TAMBIEN LOS PRODUCTOS INTERMEDIOS Y LOS PROCEDIMIENTOS DE PREPARACION DE LOS COMPUESTOS DE FORMULA (1).
ES198686307911T 1985-10-17 1986-10-13 Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo. Expired - Lifetime ES2031821T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858525654A GB8525654D0 (en) 1985-10-17 1985-10-17 Chemical compounds
GB868601667A GB8601667D0 (en) 1986-01-23 1986-01-23 Chemical compounds

Publications (1)

Publication Number Publication Date
ES2031821T3 true ES2031821T3 (es) 1993-01-01

Family

ID=26289898

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198686307911T Expired - Lifetime ES2031821T3 (es) 1985-10-17 1986-10-13 Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.

Country Status (16)

Country Link
US (2) US4906628A (es)
EP (1) EP0220044B1 (es)
CN (1) CN1009092B (es)
AU (1) AU586042B2 (es)
DE (1) DE3677316D1 (es)
DK (1) DK491186A (es)
ES (1) ES2031821T3 (es)
FI (1) FI864193A (es)
GR (1) GR3001555T3 (es)
HU (1) HU196788B (es)
IL (1) IL80296A (es)
NO (1) NO864126L (es)
NZ (1) NZ217931A (es)
PH (1) PH22428A (es)
PT (1) PT83530B (es)
ZW (1) ZW20586A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962110A (en) * 1985-03-12 1990-10-09 Smith Kline & French Laboratories Limited Pyridazinone derivatives
GB8610369D0 (en) * 1986-04-28 1986-06-04 Smith Kline French Lab Heterocyclic compounds
GB8621864D0 (en) * 1986-09-11 1986-10-15 Smith Kline French Lab Chemical process
GB8901836D0 (en) * 1989-01-27 1989-03-15 Sobio Lab Compounds
DE3913597A1 (de) * 1989-04-25 1990-11-08 Heumann Pharma Gmbh & Co Diazinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat
ES2131506T3 (es) * 1990-09-21 1999-08-01 Rohm & Haas Dihidropiridacinonas y piridacinonas como fungicidas.
CN1038249C (zh) * 1991-08-28 1998-05-06 罗姆和哈斯公司 含有二氢哒嗪酮及其相关化合物的杀菌组合物
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) * 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CA2629367C (en) * 2005-11-14 2016-05-03 Boehringer Ingelheim Vetmedica Gmbh Use of pde iii inhibitors and/or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007104035A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP1920785A1 (en) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
ES2436716T3 (es) 2008-11-25 2014-01-03 Boehringer Ingelheim Vetmedica Gmbh Pimobendan para uso en el tratamiento de la cardiomiopatía hipertrófica en gatos
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US11897867B2 (en) 2017-08-04 2024-02-13 Bayer Aktiengesellschaft 6-phenyl-4,5-dihydropyridazin-3(2H)-one derivatives as PDE3A and PDE3B inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
DE102021105255B4 (de) * 2021-03-04 2022-10-13 Festo Se & Co. Kg Vorrichtung mit über eine Verbindungsschnittstelle verbundenen Bauteilen und Verfahren zur Verbindung von Bauteilen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69407A (en) * 1982-08-23 1987-10-20 Warner Lambert Co 2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
DE3600891A1 (de) * 1986-01-15 1987-07-16 Bayer Ag 1,8-verbrueckte 4-chinolon-3-carbonsaeuren und diese enthaltende arzneimittel

Also Published As

Publication number Publication date
NZ217931A (en) 1989-04-26
FI864193A (fi) 1987-04-18
PT83530B (pt) 1989-05-31
PT83530A (en) 1986-11-01
HU196788B (en) 1989-01-30
GR3001555T3 (en) 1992-11-23
HUT41769A (en) 1987-05-28
US5066653A (en) 1991-11-19
AU6416686A (en) 1987-04-30
CN86106546A (zh) 1987-05-20
DE3677316D1 (de) 1991-03-07
CN1009092B (zh) 1990-08-08
EP0220044A3 (en) 1988-02-24
PH22428A (en) 1988-09-12
DK491186D0 (da) 1986-10-14
NO864126L (no) 1987-04-21
DK491186A (da) 1987-04-18
US4906628A (en) 1990-03-06
EP0220044A2 (en) 1987-04-29
FI864193A0 (fi) 1986-10-16
EP0220044B1 (en) 1991-01-30
NO864126D0 (no) 1986-10-16
ZW20586A1 (en) 1988-05-25
AU586042B2 (en) 1989-06-29
IL80296A (en) 1990-06-10

Similar Documents

Publication Publication Date Title
ES2031821T3 (es) Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
ES2021266B3 (es) Nuevos derivados de quinazolina, procedimiento para su produccion y composiciones farmaceuticas que los contienen.
ATE127801T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung.
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
ATE9793T1 (de) 5-oxo- und 5-thioxoproline, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
DK162519C (da) Dihydropyridazinonderivater og fremgangsmaade til fremstilling deraf samt farmaceutisk praeparat indeholdende forbindelserne
ATE5258T1 (de) (piperidinylalkyl)chinazolin-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ATE42556T1 (de) Thieno-triazolo-1,4-diazepino-2-carbonsaeureamid , verfahren zur ihrer herstellung und pharmazeutische zusammensetzung.
MX162950B (es) Procedimiento para preparar derivados de acidos piridoncarboxilicos
IE792074L (en) Pyran- and thiopyran-fused heterocyclic compounds
DK0639179T3 (da) 23-oxaderivater i D-vitaminserien, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse som lægemidler
ES2052028T3 (es) Un metodo para preparar compuestos diarilicos anti-ateroscleroticos.
ATE97901T1 (de) Cephalosporinderivate, verfahren zu ihrer herstellung sowie entsprechende pharmazeutische praeparate.
ATE6778T1 (de) Chinazolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
HUP0004142A2 (hu) 5-HT1F agonista hatású karboxamidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
ES2058177T3 (es) Nuevos derivados de alcanosulfonanilida, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
DK327286A (da) Indolcarboxamidderivater og salte deraf, deres fremstilling og anvendelse som laegemidler samt mellemprodukter til deres fremstilling
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
ES2061530T3 (es) 9-amino-1,4-etano-1,2,3,4-tetrahidroacridina y compuestos afines, intermediarios y un procedimiento para la preparacion de los mismos y su uso como medicamentos.
DE3570874D1 (en) 1,4-dihydropyridine hydroxyamines, process for their preparation and their use as pharmaceutical agents
ES8600242A1 (es) Un procedimiento para la preparacion de dihidropiridinas.
ES8201979A1 (es) Procedimiento para la obtencion de derivados de bifeni- lil-azoliletano
PT82550B (pt) Processo de preparacao de derivados de 1,3-oxatiano e de composicoes farmaceuticas que os contem
ES2035849T3 (es) Procedimiento para preparar derivados de eter difenilico.
ATE101610T1 (de) Indol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 220044

Country of ref document: ES